La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Agios Pharmaceuticals a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Agios Pharmaceuticals..

Agios Pharmaceuticals (NASDAQ:AGIO) Azioni, Catena delle Opzioni

Agios Pharmaceuticals

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals Inc

AGIOS PHARMACEUTICALS ORD

Biotech

General

AGIO

Agios Pharmaceuticals Announced It Will Present New Data And Results From Its Phase 3 Study On AG-946 At The 66th American Society Of Hematology Annual Meeting In San Diego, California From December 7-10, 2024

6 analysts have shared their evaluations of Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $53.5, with a high estimate of $56.00 and a low estimate of $51.00. This current average represents a 3.17% decrease from the previous average price target of $55.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1730487646_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of Alnylam Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$53.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$51.00</td>
<td>-</td>
</tr>
<tr>
<td>Danielle Brill</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$51.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Berens</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$56.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Alnylam Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Alnylam Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Alnylam Pharmaceuticals's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AGIO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Alnylam Pharmaceuticals analyst ratings.</a>
<h2>All You Need to Know About Alnylam Pharmaceuticals</h2>
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
<h3>Unraveling the Financial Story of Alnylam Pharmaceuticals</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Alnylam Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 28.35% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Alnylam Pharmaceuticals's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -1115.71%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Alnylam Pharmaceuticals's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -13.69%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -11.85%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.1.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)

RBC Capital analyst Gregory Renza reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Outperform and maintains $55 price target.

News

Price Target

Reiteration

RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $55 Price Target

Scotiabank analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Sector Outperform and raises the price target from $51 to $53.

Scotiabank Maintains Sector Outperform on Agios Pharmaceuticals, Raises Price Target to $53

WIIM

Agios Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 revenue results.

Guidance

Agios Expects Cash And Equivalents, Together With Anticipated Product Revenue And Interest Income, To Provide Financial Independence To Prepare For Potential PYRUKYND Launches, Advance Existing Programs, And Expand Pipeline

Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) reported quarterly sales of $8.96 million which missed the analyst consensus estimate of $9.46 million by 5.25 percent. This is a 21.15 percent increase over sales of $7.40 million the same period last year.

Earnings

Earnings Misses

Agios Pharmaceuticals Q3 Sales $8.96M Miss $9.46M Estimate

Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) will release its quarterly earnings report on Thursday, 2024-10-31. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Agios Pharmaceuticals to report an earnings per share (EPS) of $-1.01.
Anticipation surrounds Agios Pharmaceuticals's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Overview of Past Earnings</h3>
Last quarter the company missed EPS by $0.10, which was followed by a 1.21% drop in the share price the next day.
Here's a look at Agios Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.59</td>
<td>-1.65</td>
<td>-1.65</td>
<td>-1.70</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.69</td>
<td>-1.45</td>
<td>-1.72</td>
<td>-1.64</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>-0.0%</td>
<td>-1.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730297000_0.png" alt="eps graph" />
<h3>Analysts' Perspectives on Agios Pharmaceuticals</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Agios Pharmaceuticals.
Analysts have given Agios Pharmaceuticals a total of 5 ratings, with the consensus rating being Outperform. The average one-year price target is $53.6, indicating a potential 14.46% upside.
<h3>Analyzing Ratings Among Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Veracyte, Catalyst Pharmaceuticals and Geron, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>For Veracyte, analysts project an Buy trajectory, with an average 1-year price target of $36.17, indicating a potential 22.76% downside.</li>
<li>The consensus outlook from analysts is an Buy trajectory for Catalyst Pharmaceuticals, with an average 1-year price target of $30.33, indicating a potential 35.23% downside.</li>
<li>Geron is maintaining an Outperform status according to analysts, with an average 1-year price target of $6.33, indicating a potential 86.48% downside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Veracyte, Catalyst Pharmaceuticals and Geron, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agios Pharmaceuticals</td>
<td>Outperform</td>
<td>28.35%</td>
<td>$7.12M</td>
<td>-13.69%</td>
</tr>
<tr>
<td>Veracyte</td>
<td>Buy</td>
<td>26.69%</td>
<td>$77.91M</td>
<td>0.51%</td>
</tr>
<tr>
<td>Catalyst Pharmaceuticals</td>
<td>Buy</td>
<td>23.23%</td>
<td>$107.31M</td>
<td>6.97%</td>
</tr>
<tr>
<td>Geron</td>
<td>Outperform</td>
<td>2941.38%</td>
<td>$865K</td>
<td>-20.68%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Agios Pharmaceuticals ranks at the bottom for Revenue Growth among its peers. It also ranks at the bottom for Gross Profit. For Return on Equity, it is at the bottom.
<h3>About Agios Pharmaceuticals</h3>
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
<h3>Financial Insights: Agios Pharmaceuticals</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Agios Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 28.35% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Agios Pharmaceuticals's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -1115.71%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -13.69%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -11.85%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Agios Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/AGIO/earnings">To track all earnings releases for Agios Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Agios Pharmaceuticals

Agios Completes Enrollment In Phase 3 RISE UP Study Of Mitapivat For Sickle Cell Disease

Scotiabank analyst Greg Harrison initiates coverage on Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Sector Outperform rating and announces Price Target of $51.

Initiation

Scotiabank Initiates Coverage On Agios Pharmaceuticals with Sector Outperform Rating, Announces Price Target of $51

In the latest quarter, 4 analysts provided ratings for Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Agios Pharmaceuticals and provided 12-month price targets. The average target is $54.25, accompanied by a high estimate of $56.00 and a low estimate of $51.00. A decline of 3.12% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1728568871_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Agios Pharmaceuticals among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Danielle Brill</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$51.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Berens</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$56.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$53.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Agios Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Agios Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Agios Pharmaceuticals's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Agios Pharmaceuticals's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/AGIO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Agios Pharmaceuticals analyst ratings.</a>
<h2>Unveiling the Story Behind Agios Pharmaceuticals</h2>
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
<h3>Key Indicators: Agios Pharmaceuticals's Financial Health</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Agios Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 28.35%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Agios Pharmaceuticals's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -1115.71%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -13.69%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -11.85%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.1, Agios Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

4 Analysts Have This To Say About Agios Pharmaceuticals

Raymond James analyst Danielle Brill reinstates Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Outperform and announces $51 price target.

Raymond James Reinstates Outperform on Agios Pharmaceuticals, Announces $51 Price Target

Agios Pharmaceuticals shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and cut its price target on the stock from $60 to $56.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/64d204a0a2d7e70001a19db1/andy-chen">Wolfe Research analyst Andy Chen</a> downgraded the rating for Celldex Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) from Outperform to Peer Perform. Celldex Therapeutics shares fell 8.7% to close at $32.86 on Thursday. <a href="https://www.benzinga.com/quote/cldx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Justin Patterson downgraded Bumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) from Overweight to Sector Weight. Bumble shares gained 1.9% to close at $6.44 on Thursday. <a href="https://www.benzinga.com/quote/bmbl/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58e64305b85e9300014c97f9/wamsi-mohan">B of A Securities analyst Wamsi Mohan</a> downgraded the rating for HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) from Buy to Neutral and maintained the price target of $37. HP shares gained 2.2% to close at $36.85 on Thursday. <a href="https://www.benzinga.com/quote/hpq/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners analyst Andrew Berens downgraded Agios Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) from Outperform to Market Perform while cutting the price target from $60 to $56. Agios Pharmaceuticals shares fell 2% to close at $48.05 on Thursday. <a href="https://www.benzinga.com/quote/agio/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>M<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e7b9f8a5f2b9b000115d436/josh-baer">organ Stanley analyst Josh Baer </a>downgraded the rating for Udemy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UDMY#NASDAQ">UDMY</a>) from Equal-Weight to Underweight and slashed the price target from $10 to $7.5. Udemy shares gained 1.3% to close at $8.13 on Thursday. <a href="https://www.benzinga.com/quote/udmy/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying HP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="509" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27081537/image-224-1024x509.png" alt="" class="wp-image-569695" style="width:632px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27081537/image-224-1024x509.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27081537/image-224-300x149.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27081537/image-224-768x382.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27081537/image-224.png 1330w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41064318/top-3-real-estate-stocks-that-are-preparing-to-pump-this-month">Top 3 Real Estate Stocks That Are Preparing To Pump This Month</a></li>
</ul>

Downgrades

Pre-Market Outlook

Trading Ideas

BMBL

CLDX

UDMY

This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>HC Wainwright &amp; Co. cut the price target for Travere Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) from $23 to $18. HC Wainwright &amp; Co. analyst Ed Arce maintained a Buy rating. Travere Therapeutics shares gained 3.4% to close at $15.04 on Thursday. <a href="https://www.benzinga.com/quote/TVTX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc increased the price target for Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) from $8 to $11. Keybanc analyst Michael Leshock maintained an Overweight rating. Rocket Lab shares gained 0.8% to close at $8.69 on Thursday. <a href="https://www.benzinga.com/quote/RKLB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird raised MP Materials Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>) price target from $20 to $25. Baird analyst Ben Kallo maintained an Outperform rating. MP Materials shares gained 4.6% to close at $16.90 on Thursday. <a href="https://www.benzinga.com/quote/MP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stephens &amp; Co boosted ESCO Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESE#NYSE">ESE</a>) price target from $135 to $145. Stephens &amp; Co. analyst Tommy Moll maintained an Overweight rating. ESCO Technologies shares rose 1.4% to close at $126.37 on Thursday. <a href="https://www.benzinga.com/quote/ESE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird raised Accenture plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) price target from $350 to $370. Baird analyst David Koning maintained a Neutral rating. Accenture shares gained 5.6% to close at $355.81 on Thursday. <a href="https://www.benzinga.com/quote/ACN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities raised the price target for Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) from $135 to $150. B of A Securities analyst Ruplu Bhattacharya maintained a Buy rating. Jabil gained 11.7% to close at $126.65 on Thursday. <a href="https://www.benzinga.com/quote/JBL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners cut Agios Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) price target from $60 to $56. Leerink Partners analyst Andrew Berens downgraded the stock from Outperform to Market Perform. Agios Pharmaceuticals shares fell 2% to close at $48.05 on Thursday. <a href="https://www.benzinga.com/quote/AGIO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley raised the price target for Wynn Resorts, Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) from $97 to $104. Morgan Stanley analyst Stephen Grambling upgraded the stock from Equal-Weight to Overweight. Wynn Resorts shares gained 8.2% to close at $91.03 on Thursday. <a href="https://www.benzinga.com/quote/WYNN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird cut Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) price target from $172 to $150. Baird analyst Tristan Gerra maintained an Outperform rating. Micron shares gained 14.7% to close at $109.88 on Thursday. <a href="https://www.benzinga.com/quote/MU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley slashed Udemy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UDMY#NASDAQ">UDMY</a>) price target from $10 to $7.5. Morgan Stanley analyst Josh Baer downgraded the stock from Equal-Weight to Underweight. Udemy shares gained 1.3% to close at $8.13 on Thursday. <a href="https://www.benzinga.com/quote/UDMY/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying MU stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="473" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27080306/image-223-1024x473.png" alt="" class="wp-image-569670" style="width:578px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27080306/image-223-1024x473.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27080306/image-223-300x139.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27080306/image-223-768x355.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27080306/image-223.png 1430w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/41061511/costco-scholastic-and-3-stocks-to-watch-heading-into-friday">Costco, Scholastic And 3 Stocks To Watch Heading Into Friday</a></li>
</ul>

RKLB

TVTX

WYNN

Micron To $150? Here Are 10 Top Analyst Forecasts For Friday

Leerink Partners analyst Andrew Berens downgrades Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) from Outperform to Market Perform and lowers the price target from $60 to $56.

Leerink Partners Downgrades Agios Pharmaceuticals to Market Perform, Lowers Price Target to $56

Cantor Fitzgerald analyst Eric Schmidt reiterates Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Overweight.

Cantor Fitzgerald Reiterates Overweight on Agios Pharmaceuticals

RBC Capital analyst Gregory Renza reiterates Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Outperform and maintains $55 price target.

RBC Capital Reiterates Outperform on Agios Pharmaceuticals, Maintains $55 Price Target

Health Care

The FDA Granted Orphan Drug Designation To Agios Pharmaceuticals' Tebapivat (AG-946) For Myelodysplastic Syndromes

Agios Pharmaceuticals shares are trading higher after the company announced it will receive $1.1 billion in milestone payments.

Here's the major earnings before the open tomorrow

Agios Pharmaceuticals GAAP EPS of $16.22 beats by $7.53, revenue of $8.96M misses by $0.54M

Reports Q3 revenue $9.0M, consensus $9.46M. Cash, cash equivalents and marketable securities as of September 30, 2024, were $1.7B compared to $806....

Agios Pharmaceuticals reports Q3 EPS $16.22, consensus $1.11

Agios Pharmaceuticals, Inc. (AGIO) Q3 2024 Earnings Call Transcript

TD Cowen analyst Marc Frahm has maintained their bullish stance on AGIO stock, giving a Buy rating on October 23. Marc Frahm has given his Buy rati...

Agios Pharma: Buy Rating Backed by Strong Financial Performance and Promising Clinical Outcomes

Agios Pharmaceuticals ( ($AGIO) ) has released its Q3 earnings. Here is a breakdown of the information Agios Pharmaceuticals presented to its inves...

Agios Pharmaceuticals Reports Robust Q3 2024 Results

Scotiabank raised the firm's price target on Agios Pharmaceuticals (AGIO) to $53 from $51 and keeps an Outperform rating on the shares. The company...

Agios Pharmaceuticals price target raised to $53 from $51 at Scotiabank

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Agios Pharma (AGIO – Research Report) today. The company's shares open...

Bank of America Securities Reaffirms Their Buy Rating on Agios Pharma (AGIO)

Analysts fell to the sidelines weighing in on Bristol-Myers Squibb (BMY – Research Report) and Agios Pharma (AGIO – Research Report) with neutral r...

Analysts' Top Healthcare Picks: Bristol-Myers Squibb (BMY), Agios Pharma (AGIO)

Agios Pharmaceuticals (AGIO) announced that new data on mitapivat and tebapivat, AG-946, the company's PK activators, will be featured in oral and ...

Agios Pharmaceuticals to present new data on mitapivat, tebapivat

ABEV

ALGM

ALNY

AMKBY

APTV

ARGX

ATGFF

AVNT

BALL

BAND

BBVA

BNPQF

CCRD

CIFR

CMCSA

CMPS

CPSH

DFIN

DINO

FLWS

FNMA

GNRC

GPRE

IDCC

IDXX

INSM

ISNPY

ITRI

Press Releases

Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024

Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused

Agios Reports Business Highlights and Second Quarter 2024 Financial Results

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024

Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)

Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024

Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease

Agios Reports Business Highlights and Third Quarter 2024 Financial Results

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition

Comments

Agios Pharmaceuticals

Agios Pharmaceuticals (AGIO) Opzioni

Agios Pharmaceuticals (NASDAQ:AGIO) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO